Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The decision marks a pivotal moment for the Massachusetts-based biotech giant
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Subscribe To Our Newsletter & Stay Updated
